This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Calvo, E. Articles by Baselga, J. Search for Related Content PubMed PubMed Citation Articles by Calvo, E. Articles by Baselga, J.

Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Emiliano Calvo, José Baselga

From Vall d'Hebron University Hospital, Universidad Autónoma de Barcelona, Barcelona, Spain.

Address reprint requests to: José Baselga, MD, Department of Medical Oncology, Vall d'Hebron University Hospital, Paseo Vall d'Hebron, 119-129, 08035 Barcelona, Spain; jbaselga{at}vhebron.net

The identification of somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) in non–small-cell lung cancer (NSCLC) and their correlation with response to EGFR inhibitors has become an important event in the fields of cancer genetics and therapeutics. The initial observation of a higher response to gefitinib and erlotinib in patients of Asian origin was followed by the discovery that they harbor more frequent EGFR mutations in NSCLC; this raises the issue of ethnic diversity in the pathogenesis of given tumors. In a similar fashion, amplification of the closely related HER2 gene, which could also have implications for the treatment of NSCLC, is also more frequent in East Asian patients. On the other hand, EGFR gene amplification may be more prevalent in Western populations. The implication of these findings is that ethnicity may indicate different genetic backgrounds in common tumors that may influence clinical outcome and response to therapy. Therefore, in clinical trials with tyrosine kinase inhibitors and other molecular-targeted therapies, the inclusion of a global population appears to be required.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				H. Alvarez, A. Corvalan, J. C. Roa, P. Argani, F. Murillo, J. Edwards, R. Beaty, G. Feldmann, S.-M. Hong, M. Mullendore, et al. Serial Analysis of Gene Expression Identifies Connective Tissue Growth Factor Expression as a Prognostic Biomarker in Gallbladder Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2631 - 2638. [Abstract] [Full Text] [PDF]

				M. Peipp, T. Schneider-Merck, M. Dechant, T. Beyer, J. J. Lammerts van Bueren, W. K. Bleeker, P. W. H. I. Parren, J. G. J. van de Winkel, and T. Valerius Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations J. Immunol., March 15, 2008; 180(6): 4338 - 4345. [Abstract] [Full Text] [PDF]

				C. M. Rudin, W. Liu, A. Desai, T. Karrison, X. Jiang, L. Janisch, S. Das, J. Ramirez, B. Poonkuzhali, E. Schuetz, et al. Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity J. Clin. Oncol., March 1, 2008; 26(7): 1119 - 1127. [Abstract] [Full Text] [PDF]

				L.-Y. Choong, S. Lim, M. C.-S. Loh, X. Man, Y. Chen, W. Toy, M. Pan, C.-S. Chen, A. Poonepalli, M. P. Hande, et al. Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics Mol. Cancer Ther., November 1, 2007; 6(11): 2828 - 2842. [Abstract] [Full Text] [PDF]

				A. Ogino, H. Kitao, S. Hirano, A. Uchida, M. Ishiai, T. Kozuki, N. Takigawa, M. Takata, K. Kiura, and M. Tanimoto Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non Small Cell Lung Cancer Cell Line Cancer Res., August 15, 2007; 67(16): 7807 - 7814. [Abstract] [Full Text] [PDF]

				M. V. Karamouzis, J. R. Grandis, and A. Argiris Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas JAMA, July 4, 2007; 298(1): 70 - 82. [Abstract] [Full Text] [PDF]

				M.-S. Tsao, G. Liu, and F. A. Shepherd Serum Proteomic Classifier for Predicting Response to Epidermal Growth Factor Receptor Inhibitor Therapy: Have We Built a Better Mousetrap? J Natl Cancer Inst, June 6, 2007; 99(11): 826 - 827. [Full Text] [PDF]

				T. Okabe, I. Okamoto, K. Tamura, M. Terashima, T. Yoshida, T. Satoh, M. Takada, M. Fukuoka, and K. Nakagawa Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification Cancer Res., March 1, 2007; 67(5): 2046 - 2053. [Abstract] [Full Text] [PDF]

				G. Schaefer, L. Shao, K. Totpal, and R. W. Akita Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression Cancer Res., February 1, 2007; 67(3): 1228 - 1238. [Abstract] [Full Text] [PDF]

				O. I. Olopade, G. Schwartsmann, N. Saijo, and C. R. Thomas Jr Disparities in Cancer Care: A Worldwide Perspective and Roadmap for Change J. Clin. Oncol., May 10, 2006; 24(14): 2135 - 2136. [Full Text] [PDF]